slide1
Download
Skip this Video
Download Presentation
Alzheimer’s disease in a mere blood drop !

Loading in 2 Seconds...

play fullscreen
1 / 7

Alzheimer’s disease in a mere blood drop ! - PowerPoint PPT Presentation


  • 79 Views
  • Uploaded on

1. 1. Alzheimer’s disease in a mere blood drop !. Goals and business model. Developing blood biomarkers diagnosis solutions for neurodegenerative diseases Presently focused on Alzheimer’s disease Diagnostic kits Preclinical development of disease modifiers

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Alzheimer’s disease in a mere blood drop !' - raina


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

1

1

Alzheimer’s disease in a mere blood drop !

Confidential JB/XR/IHD

goals and business model
Goals and business model

Developing blood biomarkers diagnosis solutions for neurodegenerative diseases

Presently focused on Alzheimer’s disease

Diagnostic kits

Preclinical development of disease modifiers

Stratification of clinical cohorts

Development of screening tests

Seeking partnerships in the future for

Drug development throught biomarkers detection

Manufacturing and distribution of diagnosis kits and dedicated devices

2

Confidential JB/XR/IHD

intellectual property
Intellectual Property

5 patents, fully accepted, covering from the chemical synthesis of reagents to diagnosis applications

Covered territory:

Europe : published in France, Germany, United-Kingdom, Eire, Italia, Swiss.

USA and Canada

Israel

Japan , Australia

China, India, and Brazil

3

Confidential JB/XR/IHD

rationale
Two biomarkers measured :

PKC alteration as a functional biomarker

b-amyloid binding as a specific biomarker

Red blood cells are integrators of any biomarker alteration

Limited life time meaning possibility of treatment’s monitoring

10 ml are enought to perform the assay, less than one drop

Rationale

4

Confidential JB/XR/IHD

slide5

5

Applications of our peripheral biomarkers

  • These peripheral biomarkers are validated on :
    • in vitro models (cultured cell lines, primary neuronal cultures)
    • animal models (transgenic mice TASTPM , APP/PS1)
    • Human clinical trials

Confidential JB/XR/IHD

slide6

6

Collaborative project with Pixcell Medical

Technology ,

By matching the two technologies,creating the standard for the Point Of Care Diagnosis in Neurology in order ton diagnose and to follow the personalize patient’s treatment

Confidential JB/XR/IHD

slide7

7

MARKET

This device is first dedicated to the POC market :

- Neurologists

- Hospitals

For the prupose of :

- Initial Diagnosis

- Treatment monitoring and companion test

Confidential JB/XR/IHD

ad